Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Avidity Biosciences (RNA) Operating Expenses: 2018-2024

Historic Operating Expenses for Avidity Biosciences (RNA) over the last 7 years, with Dec 2024 value amounting to $389.8 million.

  • Avidity Biosciences' Operating Expenses rose 100.34% to $201.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $633.3 million, marking a year-over-year increase of 89.16%. This contributed to the annual value of $389.8 million for FY2024, which is 59.01% up from last year.
  • Avidity Biosciences' Operating Expenses amounted to $389.8 million in FY2024, which was up 59.01% from $245.2 million recorded in FY2023.
  • Avidity Biosciences' Operating Expenses' 5-year high stood at $389.8 million during FY2024, with a 5-year trough of $51.1 million in FY2020.
  • In the last 3 years, Avidity Biosciences' Operating Expenses had a median value of $245.2 million in 2023 and averaged $274.4 million.
  • Data for Avidity Biosciences' Operating Expenses shows a peak YoY soared of 159.85% (in 2020) over the last 5 years.
  • Over the past 5 years, Avidity Biosciences' Operating Expenses (Yearly) stood at $51.1 million in 2020, then surged by 149.45% to $127.4 million in 2021, then skyrocketed by 47.70% to $188.1 million in 2022, then surged by 30.31% to $245.2 million in 2023, then skyrocketed by 59.01% to $389.8 million in 2024.